Protective anti-tumor vaccination against glioblastoma expressing the MHC class II transactivator CIITA
Glioblastoma is the most malignant tumor of the central nervous system. Current treatments based on surgery, chemotherapy, and radiotherapy, and more recently on selected immunological approaches, unfortunately produce dismal outcomes, and less than 2% of patients survive after 5 years. Thus, there...
Zapisane w:
| Główni autorzy: | , , , , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Frontiers Media S.A.
2023-03-01
|
| Seria: | Frontiers in Immunology |
| Hasła przedmiotowe: | |
| Dostęp online: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1133177/full |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|